Wellcome Trust, Cambridge, United Kingdom; Designated Representative: Timothy Jinks, PhD
The Wellcome Trust supports the brightest minds in biomedical research and the medical humanities, with the aim of improving human and animal health. The Wellcome Trust has nominated Dr. Timothy Jinks to serve as their designated representative.
Dr. Jinks is the Head of Wellcome Trust's Drug Resistant Infections Priority Program, leading Wellcome's efforts directed at reducing the threat of antimicrobial resistance. In his preceding role he led development of Wellcome's strategic plan to address drug resistant infections. Previously in Wellcome's Innovations Division, he was responsible for a portfolio of over a dozen early stage product development projects covering therapeutics, diagnostics and devices spanning across therapeutic areas such as infectious diseases and oncology. He is a member of the CARB-X Joint Oversight Committee, the Longitude Prize Committee and is Non-Executive Director of Reviral Ltd. Prior to joining the Trust in 2012 he has over a decade of industry experience, most recently as a consultant providing business development, licensing and commercial research services.
His scientific background is as a chemist turned molecular biologist having studied at University of Georgia and Princeton University, with academic research experience at Harvard Medical School, Dana Farber Cancer Institute and the MRC National Institute for Medical Research.
